Company profile for MigVax

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

MigVax was established as SPV by MIGAL, which granted MigVax an exclusive worldwide license to make, use and practice the vaccine technology for the development, manufacture, and commercialization of vaccine for viruses in humans, starting with the COVID-19. The COVID-19 vaccine project initiated upon a inter-disciplinary research team successful development of a vaccine against Infectious Bronchitis Virus (IBV), an avian (...
MigVax was established as SPV by MIGAL, which granted MigVax an exclusive worldwide license to make, use and practice the vaccine technology for the development, manufacture, and commercialization of vaccine for viruses in humans, starting with the COVID-19. The COVID-19 vaccine project initiated upon a inter-disciplinary research team successful development of a vaccine against Infectious Bronchitis Virus (IBV), an avian (poultry) Coronavirus with high similarity to today’s human COVID-19 that uses the same infection mechanism.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Israel
Address
Address
Tarshish St. Qiryat Shmona, Hazafon, Israel 11016
Telephone
Telephone
+972-4-6953511
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.contractpharma.com/contents/view_breaking-news/2022-06-09/catalent-and-migvax-to-develop-oral-covid-vaccine/

CONTRACTPHARMA
10 Jun 2022

https://www.businesswire.com/news/home/20210610005425/en

BUSINESSWIRE
10 Jun 2021

https://www.businesswire.com/news/home/20210610005425/en/MigVax%E2%80%99s-Subunit-Oral-COVID-19-Vaccine-Preclinical-Trial-Demonstrates-Effectivity-as-a-Booster

BUSINESSWIRE
10 Jun 2021

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty